Bioregenx (BRGX) Amortization of Deferred Charges (2024 - 2025)
Bioregenx's quarterly Amortization of Deferred Charges came in at $1976.0 in Q3 2025, down 77.05% year-on-year from $8609.0 in Q3 2024, and up 265.22% quarter-over-quarter from -$1196.0 in Q2 2025.
Bioregenx has reported Amortization of Deferred Charges for 2 years, with the latest figure at $1976.0 in Q3 2025.
- For the quarter ending Q3 2025, Amortization of Deferred Charges fell 77.05% year-over-year to $1976.0; the trailing twelve-month figure through Mar 2026 stood at $780.0 (down 98.05% YoY), and the FY2025 full-year result was $2295.0, down 95.38% from the prior year.
- Amortization of Deferred Charges for Q3 2025 stood at $1976.0, up from -$1196.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $16213.0 in Q4 2024, with the low at -$1196.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn |
| 10 | Bioregenx | - | - | 348,288.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1,976.00 |
| Sep 30, 2025 | 1,976.00 |
| Jun 30, 2025 | -1,196.00 |
| Jun 30, 2025 | -1,196.00 |
| Mar 31, 2025 | 1,515.00 |
| Mar 31, 2025 | 1,515.00 |
| Dec 31, 2024 | 16,213.00 |
| Dec 31, 2024 | 16,213.00 |
| Sep 30, 2024 | 8,609.00 |
| Sep 30, 2024 | 8,609.00 |
| Jun 30, 2024 | 13,573.00 |
| Jun 30, 2024 | 13,573.00 |
| Mar 31, 2024 | 11,228.00 |
| Mar 31, 2024 | 11,228.00 |